Accelerate therapy development with real-world multimodal data

Advance discovery, innovation, and increase the likelihood of trial success with real-world clinical and molecular data, including DNA, RNA, and whole slide pathology images.

Contact Us

Supporting Key Development Milestones


    Discover novel biomarkers

    Leverage real-world multimodal data and bioinformatics expertise to identify disease subtypes and power discovery approaches to lead to novel therapeutic opportunities

    Read case study

    Generate and validate hypotheses

    Analyze your target of interest and identify the most appropriate patient population to evaluate for your therapy program

    Read case study

    Design late stage clinical trials

    Design trials, validate biomarker strategies, define optimal populations to study and assess execution feasibility. Plus, conduct trial simulation and survival analysis to support trial success

    Watch replay

Tempus lens

Powering Our Data Collaborations

Tempus Lens is a comprehensive, real-world, multi-modal data platform that enables Life Science companies to leverage a self-service model to uncover new insights across the research and development spectrum to make smarter decisions and launch molecules more efficiently.

Image: Progression-Free Survival Curve
Learn more

image description

How We Partner

Tempus establishes joint research teams combining disciplines from computational biology, medical, bioinformatics, and machine learning to work alongside your teams with a goal of accelerating therapy development.

Tempus Explore

Tempus bioinformatics experts help you answer your oncology research questions and meet your research objectives efficiently

Data Licenses

Our data licensing partnership provides you with access to de-identified multi-modal data to support iterative research and development objectives using the tools you are most comfortable with

Top pharmaceutical and biotech companies trust Tempus to inform therapy development


  • 90%

    of the top 20 pharma oncology companies

  • 200+

    biopharma companies

image description

We are very pleased to collaborate with Tempus to enhance our data-driven R&D strategy and glean critical insights that will deepen our understanding of complex tumor biology, enhance access to predictive preclinical models, and increase the probability of clinical success across our diverse pipeline.

Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca

Learn more about our partnership with AstraZeneca

We are looking forward to working together now and in the future, as we continue to progress our current clinical candidates, test rational combinations, and bring forward new ones, with the goal of getting medicines to patients as quickly as possible.

Jorge DiMartino, M.D., Ph.D., Chief Medical Officer and Executive Vice President, Clinical Development, Kronos Bio

Learn more about our partnership with Kronos Bio

Our collaboration with Tempus provided valuable insights to prioritize disease indications based on target expression and its relationship with clinical outcomes. The breadth of the Tempus database allowed us to correlate response of many standard therapeutic regimens to target expression to support our clinical trial plans.

Jonghwa Won, Executive Vice President, Head of Early Development, ABL Bio

Tempus is a leader in the field of personalized medicine, and like Genmab, Tempus has a mission to improve the lives of cancer patients. We are looking forward to expanding our exciting partnership with them and to the possibility of discovering important new oncology targets and biomarkers.

Jan van de Winkel, Ph.D., Chief Executive Officer, Genmab

The Tempus Difference

  • 6M+

    de-identified research records to power scientific discovery

  • 1M+

    records with imaging data

  • 800K+

    records with matched clinical data linked with genomic information

  • ~200K

    records with whole transcriptomic profiles

  • 25x larger

    database than the Cancer Genome Atlas, which we believe to be the largest public genomic database, based on petabytes of data

image description

News & Insights

view all RESOURCES

    Learn how AstraZeneca employs multimodal data to increase the probability of technical success of all Phase 3 oncology studies.

    Watch replay

    We spoke with Gilead experts to learn how the company uses multimodal data to achieve early successes in translational biomarker research and discovery.

    Watch replay

    Tempus signs strategic collaboration agreement with AstraZeneca to advance oncology therapeutics

    Read press release

    Tempus announces agreement with Janssen R&D to leverage AI/ML and real-world evidence to enhance the discovery and development of oncology therapies

    Read press release

    Using molecular signatures of Pancreatic Ductal Adenocarcinoma (PDAC) for targeting discovery

    Read case study

    Pairing sequencing, analytics, and data licensing to uncover new R&D insights

    Read case studies

See how one of the industry’s largest, structured real-world datasets can support you throughout the therapy development process.